by [email protected] | Aug 15, 2022 | Blog
Introducing… Timely resource based on index dates with ability to track time-varying events Patient-centric insights about treatment journey De-identified, tokenized, HIPAA-compliant Views You Can Use Collect the variables to...
by [email protected] | Jul 26, 2022 | Blog
Want to learn more about STATinMED and the power of RWD Insights? Here we share some common questions, with answers about our data source and approach. Is your data source HIPAA-compliant? Yes, our data source is de-identified, tokenized, and meets the...
by [email protected] | Jun 6, 2022 | Blog
It’s been a busy Spring conference season. Read more about our data and presentations below. We have access to more than 80% of the US healthcare system with patient-level data across all-provider types. See how we support evidence generation needs and let us...
by [email protected] | Mar 24, 2022 | Blog
Study Purpose and Population Epidemiology of rare diseases is important for clinicians to consider, as prevalence and incidence inform the healthcare community about likelihood of disease within an at-risk population. Studies in epidemiology also help to support...
by [email protected] | Mar 14, 2022 | Blog
STATinMED RWD Insights Our advisory and linkage services help clients to develop the ideal data lake, sourced with curated data that is aligned with research goals. With access to more than 80% of the US healthcare system, we use patient-level data across all-provider...
by [email protected] | Jan 31, 2022 | Blog
For years, market access teams within the biopharmaceutical industry have relied on regional, state and national medical and pharmacy covered lives data to size and scale their markets, identify targets, and set priorities for their strategy and contract negotiations....
